Concepedia

Sandra Bak Mueller

SB

Statistics

Publications

17

Citations

1.3K

H-Index

16

Active since

1991

Affiliations

Pfizer (United States)(Current)

Warde Medical Laboratory

Gaertner (United States)

Time Warner (United States)

Institute for Atherosclerosis Research

Sandra Bak Mueller is an author at Pfizer (United States) specializing in cholesterol metabolism, pharmacology, and plasma cholesterol levels.

Publications per year

1991–2007

17

Publications

17

Inhibition of Sphingomyelin Synthesis Reduces Atherogenesis in Apolipoprotein E–Knockout Mice

Tae‐Sik Park, Robert L. Panek, Sandra Bak Mueller et al. · Circulation · 2004 · 222 citations · Full text

, , +17

Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation.

Thomas Bocan, Sandra Bak Mueller, Paul D. Uhlendorf et al. · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · 1991 · 157 citations

, , +17

A specific 15-lipoxygenase inhibitor limits the progression and monocyte–macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit

Thomas Bocan, Wendy S. Rosebury, Sandra Bak Mueller et al. · Atherosclerosis · 1998 · 117 citations

, , +14

The relationship between the degree of dietary-induced hypercholesterolemia in the rabbit and atherosclerotic lesion formation

Thomas Bocan, Sandra Bak Mueller, Paul D. Uhlendorf et al. · Atherosclerosis · 1993 · 114 citations

, , +12

The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits

Thomas Bocan, Brian R. Krause, Wendy S. Rosebury et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2000 · 113 citations · Full text

, , +17

1–5 of 17